Search Medical Condition
Please enter condition
Please choose location

Willow Grove, Pennsylvania Clinical Trials

A listing of Willow Grove, Pennsylvania clinical trials actively recruiting patient volunteers.

RESULTS

Found (434) clinical trials

Long Term Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Participant has successfully completed Studies 15-AVP-786-301, 15-AVP-786-302, or 12-AVR-131. Participants will be enrolled in the study for approximately 56 weeks (participants who have a follow-up visit 3 months after the last dose of treatment will be enrolled for approximately 64 weeks). Approximately 700 participants will be enrolled at approximately 135 ...

Phase

0.0 miles

Learn More »

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

This study will assess the effects of each of the two therapies given separately, both targeting amyloid, on cognition, global clinical status, and underlying pathology in participants at risk for the onset of clinical symptoms of Alzheimer's disease (AD). Cognitively unimpaired individuals with two APOE4 genes and age 60 to ...

Phase

0.0 miles

Learn More »

An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia

This is a randomized (study drug assigned by chance), double-blind (neither the researchers nor the participants know what treatment the participant is receiving), multi-center (more than one hospital or medical school team work on a medical research study), placebo-controlled, parallel-group study in participants who are asymptomatic and at risk for ...

Phase

0.0 miles

Learn More »

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK) **Please note that the study is no longer enrolling patients for Groups A, B, C, and E.

Phase

0.0 miles

Learn More »

Dimethyl Fumarate (DMF) Observational Study

Patients aged 12 to under 18 may be included where enrollment of pediatric patients in this study is considered observational and is permissible by local regulations.

Phase N/A

0.0 miles

Learn More »

Utility of PharmacoGenomics for Reducing Adverse Drug Effects

UPGRADE aims to see whether data from Pharmacogenomic Testing (PGx) can help physicians manage patient medication regimens and assess if the testing has an effect on reducing adverse drug reactions, hospitalizations and emergency department visits. The way an individual processes a drug is in part determined by their genes, and ...

Phase N/A

0.0 miles

Learn More »

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is ...

Phase

0.0 miles

Learn More »

Efficacy Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Eligible participants for this study must have a diagnosis of probable AD and must have clinically meaningful agitation secondary to AD. This is a multicenter, randomized, placebo-controlled study, consisting of 12 weeks of treatment. Approximately 380 participants will be enrolled at approximately 60 centers in North America. Study medication will ...

Phase

0.0 miles

Learn More »

CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The final efficacy and ...

Phase

0.0 miles

Learn More »

A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia

The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer's disease (AD) dementia.

Phase

0.0 miles

Learn More »